Drug Trial Radar · NCT06653296
A Dose-Response Safety Study of ENX-102 in Patients With GAD
Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Dec 9, 2024
Primary completion
Jun 23, 2025
Study completion Jun 23, 2025
Sponsor
- Lead sponsor
- Engrail Therapeutics INCIndustry
- Sponsor type
- Industry
- First posted
- Oct 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ENX-102 and determine a dose-response for the effects of ENX-102 in patients with GAD
Conditions
- General Anxiety Disorder
Interventions
ENX-102Drug
Four weeks of ENX-102 (0.5, 1, or 3 mg) in capsule form followed by 2 weeks of tapered dose, taken orally once daily in the evening for a 6-week total treatment period
PlaceboDrug
Six weeks of placebo in capsule form taken orally once daily in the evening for a 6-week total treatment period
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerabilityTime frame: 4 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
MAC Clinical Research
Blackpool, United Kingdom
MAC Clinical Research
Manchester, United Kingdom
MAC Clinical Research
Liverpool, UK, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.